Role of a mouse monoclonal IgE antibody in passive transfer of immunity to Schistosoma japonicum infection

Kojima, Satoshi; Janecharut, Tuenta; Hata, Hidekazu; Niimura, M.

doi:10.1590/s0074-02761987000800045

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of them, paramyosin, a 97 kDa myofibrillar protein, can induce effective anti-infective immune protection (21). Previous study showed monoclonal anti-paramyosin antibody conferred good protection against Schistosoma japonicum in mice (22). A recent study showed that the recombinant paramyosin protein also conferred significant levels of protection against S. japonicum infection in water buffalo (19).…”

Section: Resultsmentioning

confidence: 99%

Proteomics Analysis of Hydatigera taeniaeformis Metacestode Stage

Guo

2020

Front. Vet. Sci.

View full text Add to dashboard Cite

Hydatigera taeniaeformis (H. taeniaeformis) is one of the most robust of tapeworm parasites that is widely distributed around the world. Information of proteins of H. taeniaeformis has not previously been reported. Using liquid chromatography tandem-mass spectrometry (LC-MS/MS) analysis, the proteome of H. taeniaeformis metacestode was profiled and a total of 408 proteins were identified. Of these, 26.5% (108/408) were annotated to be associated with metabolic pathways. Consistently, Gene Ontology analysis showed that those identified proteins were mainly classified into metabolic process of the biological processes. A set of metabolic enzymes, including Fructose-1,6-bisphosphate aldolase, enolase, Glucan phosphorylase, and phosphoenolpyruvate carboxykinase, were abundant in H. taeniaeformis metacestodes. In addition, some rare but interesting proteins like antigens (such as tegument protein and Antigen B) were identified. The two recombinant proteins of tegument protein and Antigen B were well-recognized by the sera from the H. taeniaeformis-infected mice. The H. taeniaeformis metacestode proteome might help to find new candidates for the immunodiagnosis and vaccine development and provide valuable information on H. taeniaeformis biology.

show abstract

Section: Resultsmentioning

confidence: 99%

Proteomics Analysis of Hydatigera taeniaeformis Metacestode Stage

Guo

2020

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…On the other hand, mice vaccinated intradermally with S. mansoni or schistosomula extracts with Mycobacterium Bovis BCG adjuvant were significantly protected against subsequent infection, and antibodies predominantly recognized paramyosin (Lanar et al 1986;Sher et al 1986). In addition, a BALB c/C3H HFl mouse monoclonal IgE antibody recognized S. japonicum paramyosin (Nara et al 1997), and showed protection (19-58%) against cercarial infection following passive transfer (Kojima et al 1987a;. Conversely, paramyosin immunogen failed to confer the same level of protection in multi-antigen DNA-based form (Tang et al 2008).…”

Section: Paramyosinmentioning

confidence: 99%

A comprehensive and critical overview of schistosomiasis vaccine candidates

et al. 2021

View full text Add to dashboard Cite

“…A hybridoma that produces a monoclonal IgE antibody to S. japonicum, SJ18ε.1, was identified [57]. This mAb was protective in an in vitro, antigen-dependent, cellular cytotoxicity assay with rat macrophages or eosinophils and also in vivo during the early phase of infection [57][58][59]. It recognizes a 97 kDa antigen, Sm-97 (Schistosoma mansoni-97), identified as paramyosin, a muscle protein unique to invertebrates [75,76].…”

Section: Vlmentioning

confidence: 99%

Reassessing therapeutic antibodies for neglected and tropical diseases

et al. 2020

Self Cite

View full text Add to dashboard Cite

In the past two decades there has been a significant expansion in the number of new therapeutic monoclonal antibodies (mAbs) that are approved by regulators. The discovery of these new medicines has been driven primarily by new approaches in inflammatory diseases and oncology, especially in immuno-oncology. Other recent successes have included new antibodies for use in viral diseases, including HIV. The perception of very high costs associated with mAbs has led to the assumption that they play no role in prophylaxis for diseases of poverty. However, improvements in antibody-expression yields and manufacturing processes indicate this is a cost-effective option for providing protection from many types of infection that should be revisited. Recent technology developments also indicate that several months of protection could be achieved with a single dose. Moreover, new methods in B cell sorting now enable the systematic identification of high-quality antibodies from humanized mice, or patients. This Review discusses the potential for passive immunization against schistosomiasis, fungal infections, dengue, and other neglected diseases.PLOS Neglected Tropical Diseases | https://doi.interactions have proved difficult to block. In addition, there has been great progress in the development of technology. Early generations of antibodies for human use were developed from mAbs developed in mice, antibodies that were then humanized. Recently, the technology used peptide and antibody display on phages, for which part of the 2018 Nobel Prize in Chemistry was awarded to Sir Gregory P. Winter [6]. More recently, new technologies have been developed to clone antibodies from memory B cells [7] or plasma B cells [8, 9], allowing the isolation of individual antibodies from patients with viral infections-approaches that can be applied to any infectious disease.A second reason for the popularity of antibodies in recent years is their success rate in clinical development. Once an antibody reaches testing in humans, it has a success rate of 17% to 25% for approval as a new medicine [10], compared with 5% to 10% for small molecules. This success rate is partly due to the exquisite selectivity of mAbs, enabling them to distinguish between closely related molecular targets. In the case of infectious disease, this selectivity can be absolute, since antibodies can be generated that are specific for the invading pathogen and do not cross-react with host tissues. This lack of cross-reactivity with human tissue can be confirmed by immunohistochemistry on both adult and embryonic tissues prior to the start of clinical trials. This is in stark contrast to small molecules, in which sometimes unexpected onand off-target safety signals are frequently seen in the later stages of clinical development, resulting in expensive late-stage attrition. In addition, antibodies show a relatively narrow range of variation in pharmacokinetic exposure, facilitating early estimation of the human effective dose. This is unlike true xenobiotics, whose metabolism an...

show abstract

Role of a mouse monoclonal IgE antibody in passive transfer of immunity to Schistosoma japonicum infection

Cited by 7 publications

References 0 publications

Proteomics Analysis of Hydatigera taeniaeformis Metacestode Stage

Proteomics Analysis of Hydatigera taeniaeformis Metacestode Stage

A comprehensive and critical overview of schistosomiasis vaccine candidates

Reassessing therapeutic antibodies for neglected and tropical diseases

Contact Info

Product

Resources

About